Literature DB >> 17571172

Endoscopic follow-up of positive fecal occult blood testing in the Ontario FOBT Project.

Lawrence Paszat1, Linda Rabeneck, Lori Kiefer, Verna Mai, Paul Ritvo, Terry Sullivan.   

Abstract

BACKGROUND: The Ontario FOBT Project is a pilot study of fecal occult blood testing (FOBT) for colorectal cancer screening conducted among age-eligible volunteers (50 to 75 years) in 12 of 37 public health regions in Ontario.
METHODS: Volunteers responded to invitations from primary care practitioners (PCPs) in six regions, and from public health programs in the remaining regions. FOBT collection kits were distributed from routine laboratory specimen collection sites, to which completed kits were returned. Results were sent to PCPs in all 12 regions, with copies sent to the study office at Cancer Care Ontario (Toronto, Ontario). Follow-up of positive results was at the discretion of the PCPs. The study files contained the unique Ontario Health Insurance Numbers, the date of the analyses, the number of satisfactory slides and the results for each slide. The Ontario Health Insurance Numbers were encrypted for each participant, and along with the study file, were linked to medical billing claims, hospital records and aggregate demographic data.
RESULTS: Among participants with positive results (men 3.5% and women 2.2%), the median time from date of FOBT analysis to date of colonoscopy was 121 days among men and 202 days among women. At the end of follow-up, after positive FOBT (six to 17 months), 73% of men and 56% of women had proceeded to colonoscopy.
CONCLUSION: Although colonoscopy appeared to be acceptable to the majority of participants with positive FOBT, accessibility problems was the likely explanation for lengthy intervals between the date of positive FOBT and its performance. Differences between the experiences of men and women require further investigation.

Entities:  

Mesh:

Year:  2007        PMID: 17571172      PMCID: PMC2658121          DOI: 10.1155/2007/569689

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  11 in total

1.  Colorectal cancer screening. Recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2001-07-24       Impact factor: 8.262

2.  A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening.

Authors:  Timothy R Church; Mark W Yeazel; Resa M Jones; Laura K Kochevar; Gavin D Watt; Steven J Mongin; Jill E Cordes; Deborah Engelhard
Journal:  J Natl Cancer Inst       Date:  2004-05-19       Impact factor: 13.506

3.  Fecal occult blood screening in the Minnesota study: role of chance detection of lesions.

Authors:  F Ederer; T R Church; J S Mandel
Journal:  J Natl Cancer Inst       Date:  1997-10-01       Impact factor: 13.506

4.  Patient tolerance of colonoscopy without sedation during screening examination for colorectal polyps.

Authors:  E Thiis-Evensen; G S Hoff; J Sauar; M H Vatn
Journal:  Gastrointest Endosc       Date:  2000-11       Impact factor: 9.427

5.  A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult.

Authors:  B Towler; L Irwig; P Glasziou; J Kewenter; D Weller; C Silagy
Journal:  BMJ       Date:  1998-08-29

6.  Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results.

Authors:  G Grazzini; G Castiglione; C Ciabattoni; F Franceschini; D Giorgi; S Gozzi; P Mantellini; P Lopane; M Perco; T Rubeca; P Salvadori; C B Visioli; M Zappa
Journal:  Eur J Cancer Prev       Date:  2004-02       Impact factor: 2.497

7.  Patterns of colorectal cancer screening uptake among men and women in the United States.

Authors:  Helen I Meissner; Nancy Breen; Carrie N Klabunde; Sally W Vernon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-02       Impact factor: 4.254

8.  Why is colonoscopy more difficult in women?

Authors:  B P Saunders; M Fukumoto; S Halligan; C Jobling; M E Moussa; C I Bartram; C B Williams
Journal:  Gastrointest Endosc       Date:  1996-02       Impact factor: 9.427

9.  Determinants of colorectal cancer screening in women undergoing mammography.

Authors:  David H Stockwell; Paula Woo; Brian C Jacobson; Renee Remily; Sapna Syngal; Jacqueline Wolf; Francis A Farraye
Journal:  Am J Gastroenterol       Date:  2003-08       Impact factor: 10.864

10.  Impact of UK Colorectal Cancer Screening Pilot on hospital diagnostic services.

Authors:  Jacqueline Price; Christine Campbell; Joanne Sells; David Weller; Harry Campbell; Margaret Kenicer; Malcolm Dunlop
Journal:  J Public Health (Oxf)       Date:  2005-05-03       Impact factor: 2.341

View more
  9 in total

1.  Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.

Authors:  Amit G Singal; Samir Gupta; Celette Sugg Skinner; Chul Ahn; Noel O Santini; Deepak Agrawal; Christian A Mayorga; Caitlin Murphy; Jasmin A Tiro; Katharine McCallister; Joanne M Sanders; Wendy Pechero Bishop; Adam C Loewen; Ethan A Halm
Journal:  JAMA       Date:  2017-09-05       Impact factor: 56.272

2.  Contribution of patient, physician, and environmental factors to demographic and health variation in colonoscopy follow-up for abnormal colorectal cancer screening test results.

Authors:  Melissa R Partin; Amy A Gravely; James F Burgess; David A Haggstrom; Sarah E Lillie; David B Nelson; Sean M Nugent; Aasma Shaukat; Shahnaz Sultan; Louise C Walter; Diana J Burgess
Journal:  Cancer       Date:  2017-05-11       Impact factor: 6.860

3.  Organizational predictors of colonoscopy follow-up for positive fecal occult blood test results: an observational study.

Authors:  Melissa R Partin; Diana J Burgess; James F Burgess; Amy Gravely; David Haggstrom; Sarah E Lillie; Sean Nugent; Adam A Powell; Aasma Shaukat; Louise C Walter; David B Nelson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12-03       Impact factor: 4.254

4.  Examining the Factors That Affect the Diagnosis of Patients with Positive Fecal Occult Blood Test Results.

Authors:  Yin-Wen Cheng; Ying-Chun Li
Journal:  Int J Environ Res Public Health       Date:  2022-06-21       Impact factor: 4.614

5.  Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems.

Authors:  Jessica Chubak; Michael P Garcia; Andrea N Burnett-Hartman; Yingye Zheng; Douglas A Corley; Ethan A Halm; Amit G Singal; Carrie N Klabunde; Chyke A Doubeni; Aruna Kamineni; Theodore R Levin; Joanne E Schottinger; Beverly B Green; Virginia P Quinn; Carolyn M Rutter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02       Impact factor: 4.254

6.  Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis.

Authors:  Douglas A Corley; Christopher D Jensen; Virginia P Quinn; Chyke A Doubeni; Ann G Zauber; Jeffrey K Lee; Joanne E Schottinger; Amy R Marks; Wei K Zhao; Nirupa R Ghai; Alexander T Lee; Richard Contreras; Charles P Quesenberry; Bruce H Fireman; Theodore R Levin
Journal:  JAMA       Date:  2017-04-25       Impact factor: 56.272

7.  Effectiveness of an organized colorectal cancer screening program on increasing adherence in asymptomatic average-risk Canadians.

Authors:  Thomas J Charters; Erin C Strumpf; Maida J Sewitch
Journal:  BMC Health Serv Res       Date:  2013-10-29       Impact factor: 2.655

8.  Fecal Immunochemical Test as a Screening Method for Colorectal Cancer in University College Hospital Ibadan, Nigeria.

Authors:  Elizabeth O Labaeka; Achiaka E Irabor; David O Irabor
Journal:  JCO Glob Oncol       Date:  2020-03

9.  Implementing a multilevel intervention to accelerate colorectal cancer screening and follow-up in federally qualified health centers using a stepped wedge design: a study protocol.

Authors:  Karen Kim; Blasé Polite; Donald Hedeker; David Liebovitz; Fornessa Randal; Manasi Jayaprakash; Michael Quinn; Sang Mee Lee; Helen Lam
Journal:  Implement Sci       Date:  2020-10-29       Impact factor: 7.327

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.